Discontinue therapy if severe diarrhoea, nausea & vomiting persists. Diarrhoea & vomiting may lead to dehydration w/ or w/o electrolyte disturbances which may progress to renal function impairment; administer electrolytes & fluids in the event of dehydration; monitor electrolyte plasma levels if relevant GI adverse effects occur. Periodically measure systemic BP. May promote formation of aneurysm &/or artery dissection; carefully consider patients w/ risk factors eg, poorly controlled HTN or a history of aneurysm. Perform frequent monitoring of complete blood counts at the beginning of each treatment cycle & around the nadir for patients receiving combination therapy w/ docetaxel, & after administration of last combination cycle. Interrupt treatment or permanently discontinue in case of specific changes in liver values (AST/ALT >3 x ULN in conjunction w/; bilirubin ≥2 x ULN & ALKP <2 x ULN). Closely monitor female & Asian patients, & those w/ low body wt [(<65 kg) in IPF & SSc-ILD treatment only] for higher risk of developing liver enzyme elevations; patients weighing <50 kg (NSCLC treatment only). Consider treatment interruption in patients who develop nephrotic syndrome signs or symptoms. Monitor patients exhibiting risk factors for renal impairment/failure. May consider discontinuation in patients who experienced grade ¾ bleeding events. Not recommended in patients w/ recent pulmonary bleeding (>2.5 mL of red blood), & centrally-located tumours w/ radiographic evidence of local invasion of major blood vessels or of cavitary or necrotic tumours; active brain metastasis. Closely monitor for signs & symptoms of cerebral bleeding in patients w/ adequately pre-treated brain metastases which were stable for ≥4 wk before start of treatment. Regularly monitor patients taking concomitant anticoagulation eg, warfarin or phenprocoumon, for changes in prothrombin time, INR or clinical bleeding episodes. Patients w/ a higher CV risk including known CAD. Consider treatment interruption in patients who develop signs or symptoms of acute myocardial ischaemia. Discontinue in patients w/ life-threatening VTE reactions. Patients w/ previous abdominal surgery, history of peptic ulceration, diverticular disease, or concomitantly using corticosteroids or NSAIDs; w/ recent history of hollow organ perforation. Permanently discontinue in patients who develop GI perforation or ischaemic colitis; reintroduce treatment after complete resolution of ischaemic colitis & careful assessment of patient's condition & other risk factors. Consider treatment interruption in patients who develop signs or symptoms of nephrotic syndrome. May impair wound healing. Patient who may develop QTc prolongation. Enhanced risk for severe reactions to soya prep in patients w/ known allergy to peanut protein. Severe renal impairment (<30 mL/min CrCl). Not recommended in patients w/ moderate (Child-Pugh B) & severe (Child-Pugh C) hepatic impairment. May affect ability to drive & use machines. Black patients. Women of childbearing potential should use highly effective contraception methods at the initiation of, during & at least 3 mth after the last dose of treatment & avoid becoming pregnant while receiving treatment. Use of an alternative highly effective contraceptive measure is advised in patients taking oral hormonal contraceptives who experience vomiting &/or diarrhoea, or other absorption-affecting conditions. Do not use during pregnancy; discontinue use if patient becomes pregnant during treatment. Discontinue breastfeeding during treatment. Childn 0-18 yr. Elderly ≥75 yr.
Sign Out
